Results
1 -
10 of
16Differences in the Susceptibility of Various Aldose Reductases to Inhibition, Progress in Anterior Eye Segment Research and Practice Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats, Diabetologia Topical Treatment of Galactose Cataracts, Progress of Lens Biochemistry Research Clinical Trials, The Polyol Paradigm and Complications of Diabetes Aldose Reductase Inhibitors and Other Potential Therapeutic Agents for the Treatment of Diabetic Neuropathy, Clinical Management of Diabetic Neuropathy Chemistry, The Polyol Paradigm and Complications of Diabetes Aldose Reductase Inhibitors for the Treatment of Diabetic Neuropathy, Diabetic Neuropathy Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats, Diabetologia Inhibition of prostaglandin-induced cyclic AMP accumulation in the rat anterior pituitary by alrestatin, Experientia